Comparative effectiveness of androgen receptor pathway inhibitor treatment intensification for metastatic hormone-sensitive prostate cancer in real-world patients
Open Access
- 1 January 2025
- journal article
- research article
- Published by XMLink in Investigative and Clinical Urology
- Vol. 66 (6) , 516-525
Abstract
Lee CH, et al. Investig Clin Urol. 2025 Oct;66:e64. https://doi.org/10.4111/icu.20250313Keywords
Funding Information
- Busan Paik Hospital, Inje University
This publication has 32 references indexed in Scilit:
- PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone‐Sensitive Prostate Cancer (mHSPC) in Real‐World Analyses?The Prostate, 2025
- Rapid and Deep Prostate‐Specific Antigen Decline is a Prognostic Marker in Metastatic Hormone‐Sensitive Prostate Cancer: A Real‐World Multi‐Intuitional AnalysisThe Prostate, 2024
- Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter studyThe Prostate, 2024
- Treatment Intensification With Novel Hormonal Therapy in Castration-Sensitive Prostate Cancer: Patient Identification and Clinical RationaleClinical Genitourinary Cancer, 2024
- Clinical Outcomes and Risk Stratification in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With New-Generation Androgen Receptor Signaling InhibitorsClinical Genitourinary Cancer, 2024
- Recomendaciones de tratamiento en el cáncer de próstata hormonosensible metastásico: selección de pacientesActas Urológicas Españolas, 2024
- Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancerAnnals of Oncology, 2023
- Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment responseWorld Journal of Urology, 2022
- Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysisEuropean Urology Focus, 2022
- Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelinesThe Prostate, 2020